Ibogaine as a Tool in the Process of Overcoming Drug Addiction
Outcomes Review moderate
AI-extracted · unverified · confirm at source
Brazilian clinical experience confirms ibogaine reduces opioid withdrawal, craving, and substance use; emphasises integration psychotherapy and proper screening as essential; estimates >30,000 treatments since 2007.
Dosing: 15–25 mg/kg oral (therapeutic); 4–5 mg/kg (psycholytic, Naranjo) (oral)
Contraindications: Pre-existing cardiac conditions / widened baseline QT interval, Liver failure (elevated INR), Psychosis, schizophrenia, Bipolar disorder (risk of manic episode), Concomitant opioid use, Concomitant CYP2D6/CYP3A4 substrate medications, Recent cocaine use (QT prolongation for 7-15 days post-cessation), Low magnesium (correctable — formal but not definitive)